MAIN TEXT
Anti-epidermal growth factor receptor (EGFR) antibodies (anti-EGFR-Ab) are effective in a subgroup of patients with metastatic colorectal cancer (CRC). Activating KRAS or NRAS mutations in codons 12, 13, 59, 61, 117 and 146 have been associated with primary resistance in randomized trials and anti-EGFR-Ab-treatment should only be administered for tumors that are wild-type (wt) at these loci [1] [2] [3] [4] [5] . In spite of this stratification, many patients do not benefit, indicating additional resistance mechanisms. BRAF V600E 6 , MAP2K1/ERK1 7 or PIK3CA 8 mutations, amplifications of KRAS 9 and of the receptor tyrosine kinases (RTKs) ERBB2, MET and FGFR1 7 have been suggested as further drivers of primary resistance. Moreover, a recently defined transcriptomic classification of CRCs into distinct subtypes found an association of the transit amplifying (TA)-subtype with cetuximab sensitivity 10 , suggesting that non-genetic molecular characteristics also influence anti-EGFR-Ab sensitivity.
Acquired anti-EGFR-Ab resistance almost invariably occurs in patients who initially benefit and this has predominantly been studied retrospectively in circulating tumor DNA (ctDNA) using targeted genetic analyses [11] [12] [13] . KRAS and NRAS mutations, as well as EGFR-exodomain mutations that alter the binding epitope for the anti-EGFR-Ab cetuximab have been found in a large proportion of patients with acquired resistance. Amplifications of MET or KRAS evolved in some patients [14] [15] [16] . The high prevalence of RAS mutations supports the notion that mechanisms of primary and acquired resistance are often similar. A small number of studies assessed acquired anti-EGFR-Ab resistance in tumor biopsies 11, 17 . These also identified RAS and EGFR mutations but their retrospective nature and the analysis of only a small number of candidate genes may have biased the results. Increased growth factor availability, for example of ligands for the EGFR or MET RTKs 18, 19 , confer anti-EGFR-Abresistance in vitro but their clinical relevance remains unknown. We undertook the first prospective trial that collected baseline (BL) biopsies immediately before initiation of single agent cetuximab and re-biopsies at the time of progressive disease (PD) from metastatic RAS wt CRCs. Biopsies were subjected to whole-exome mutation analysis, DNA-copy number analysis and to RNA-sequencing to assess primary and acquired resistance. Detailed insights into resistance mechanisms may enable more precise therapy allocation to patients who are likely to respond and open novel therapeutic opportunities for cetuximab-resistant CRCs.
RESULTS
40 patients (pts) treated with single agent cetuximab could be assessed for treatment response and had sufficient biopsy material available for molecular analysis. Sequencing of BL biopsies failed in 5pts, leaving 35 for study (Patient characteristics and Consort-diagram:
Supplementary fig.1 and table 1; Somatic mutation data: Supplementary table 2). As expected for CRC, this showed a high prevalence of TP53 and APC mutations (Fig.1a) . The median PFS and OS of this cohort were 2.6mo and 8.5mo, respectively (Supplementary fig.2a ). 20pts showed primary progression at or before the first per-protocol CT scan (scheduled at week 12). The remaining 15
were classified as patients with prolonged clinical benefit. PD-biopsies were taken shortly after radiological progression (median: 14d after cetuximab cessation) from 25/35 cases and 24 were successfully exome sequenced. Sufficient RNA for RNA-sequencing was obtained from 25 BL-and 15 matched PD-samples.
Genetic drivers of primary resistance
We first aimed to identify resistance drivers in BL-biopsies from 20 primary progressors (Fig.1b) . Oncogenic BRAF V600E mutations were present in 6pts, one in combination with an IGF1R amplification (C1035BL, see Supplementary fig.3 for integer copy number profiles). No radiological response occurred in any of these and PFS was short (Supplementary fig.2b ), supporting prior data that BRAF V600E confers resistance to single agent cetuximab 20 . C1011BL harbored a non-canonical BRAF D594F mutation, disrupting the DFG-motif of the kinase site. This is predicted to lead to a kinase-impaired BRAF variant 21 , which have been shown to paradoxically hyperactivate downstream ERK-phosphorylation when combined with oncogenic RAS alterations 22 . C1011BL indeed harbored a concomitant KRAS L19F mutation which has an attenuated phenotype compared to KRAS codon 12/13 hotspot mutations 23 . Another KRAS mutation (A18D) with an attenuated phenotype in vitro 24 was present on all 7 alleles of the polysomic chromosome 12p (Supplementary fig.4a ) in C1033BL, likely explaining resistance in this case. A KRAS G12D mutation was identified in C1032BL, which had been found to be KRAS wt prior to study entry, indicating either a false negative result of the clinical assay or KRAS intratumor heterogeneity. A KRAS amplification was present in C1028BL and an ERBB2 amplification in C1022BL (Supplementary fig.3 ). C1019BL harbored a canonical activating MAP2K1/MEK1 mutation (K57N) and a concomitant MAP2K1/MEK1 mutation (S228A) that did not influence kinase activity in a previous study 25 . Two tumors carried disrupting mutations in NF1
(C1021BL: frameshift, C1045BL: nonsense). Both showed loss of heterozygosity of the NF1-locus on Chr17 (Supplementary fig.4b ), constituting biallelic inactivation of this tumor suppressor gene. NF1
encodes for neurofibromin, a negative regulator of KRAS, whose loss leads to EGFR-inhibitor resistance in lung cancer 26 . This suggests NF1 inactivation as a novel driver of primary cetuximab resistance in CRC. The RTK ERBB3 was mutated (P590L) in C1017BL but this amino acid change had no impact on in vitro growth in a previous study 27 , questioning whether it confers cetuximab resistance.
In contrast to prior studies 7, 8 , neither PIK3CA nor FGFR1 aberrations clearly associated with resistance: 4/20pts with primary progression harbored activating PIK3CA mutations (2xE545K, G364R, and H1047R concomitant with PIK3CA amplification (Supplementary fig.4c )) but also 3/15pts with prolonged benefit (2xV344G, H1047R). A tumor with a high level FGFR1 amplification (C1037BL) and one with an FGFR1 R209H mutation (C1007BL), previously reported in Kallmann syndrome 28 , had partial responses and prolonged benefit. An EGFR amplification was found in one tumor (C1030BL) and this associated with prolonged benefit as described 7 . 5 ). There are strong similarities between subtypes of both classifications and 21/25 cases (84%) were assigned to matching subtypes, confirming robust performance (Fig.1c , see legend for subtype nomenclature and most similar subtypes). The Transit Amplifying (TA)-subtype has previously been associated with cetuximab sensitivity 10 and was significantly enriched among cases with prolonged benefit (3.4-fold, p=0.017, Fisher's exact test).
The TA-subtype is most similar to the CMS2-subtype in the CRC Consensus Molecular Subtypeclassification and the CMS2-subtype was equally enriched among patients with prolonged cetuximab benefit (2.9-fold enrichment, p=0.015 Fisher's exact test). This validates the TA/CMS2-subtypes as non-genetic predictors of single-agent cetuximab benefit.
Genetic drivers of acquired resistance
PD-biopsies from 14 metastases that radiologically progressed after prolonged clinical benefit were successfully exome sequenced (Fig.2a) , including biopsies from two different progressing metastases in C1027. We first investigated genes with a known role in cetuximab resistance. Only one acquired KRAS mutation was found among these PD-biopsies (C1005PD: G12C).
This clonally dominant mutation (Supplementary fig.3d ) was accompanied by an EGFR mutation (G322S) which has not previously been described and whose relevance is uncertain in the context of a well characterized cetuximab resistance mutation in KRAS. One biopsy acquired a KRAS amplification (C1037PD). C1024PD acquired a clonally dominant EGFR mutation which has not previously been described (D278N), locating to the EGFR extracellular domain II 30 but not affecting cetuximab binding epitopes. Expression of EGFR D278N in a CRC cell line did not confer cetuximab resistance and introduction into the 3T3 fibroblast line showed no evidence of constitutive EGFR phosphorylation (Supplementary fig.6 ), suggesting that this is a passenger mutation. No other RAS, EGFR, BRAF or ERK mutations or amplifications were detected in PD-biopsies.
Two further RTKs acquired mutations at PD: FGFR3 in C1030PD (P418L) and ALK in C1024PD (D626H). Neither located to the well defined mutational hotspots in these genes, nor have they been reported in the COSMIC cancer mutation database 31 , indicating that these may be passenger mutations. C1024PD furthermore acquired an FGFR1 amplification (Supplementary fig.3 ). However, the presence of an FGFR1 amplification in C1037BL which subsequently had a good response to cetuximab treatment (Fig.1b) fig.3 ).
Taken together, we identified known (KRAS mutations/amplifications, EGFR mutations of cetuximab binding epitopes) and novel (FGF10 amplification) cetuximab resistance drivers in four PD-biopsies. One case acquired an FGFR1 amplification and one an FGFR3 mutation with unclear relevance for resistance. Importantly, no drivers of AR were found in 9/14 (64%) biopsied metastases despite each radiologically progressing ( Supplementary Fig.8 ).
Genetic drivers of acquired resistance in ctDNA
The low prevalence of cetuximab resistance drivers in PD biopsies was striking as it contrasts with results of ctDNA analyses of this trial and others that reported the evolution of RAS and EGFR aberrations in the vast majority of patients at the time they acquired cetuximab resistance 13, 35 . We applied a ctDNA-sequencing assay targeting CRC and cetuximab resistance driver genes (Supplementary table 5 ) which simultaneously infers genome-wide copy number profiles 36 . This enabled us to correct VAFs for the influence of copy number states and to then quantify the proportion of the cancer cells that harbored resistance drivers by comparison against TP53 mutations which are usually truncal in CRC 37 . Available ctDNA from 9 cases that progressed after prolonged cetuximab benefit (5 BL/PD pairs, 4 PD only) was deep sequenced (1048x mean depth).
Known cetuximab resistance mutations in RAS, BRAF or EGFR were identified in 7/9 cases at PD (Fig.2c, Supplementary table 5 ). Furthermore, a kinase-impaired BRAF mutation (D594N) was detected in 6.8% of the cancer cell fraction in ctDNA at BL and this increased to 37.4% at PD in C1030 (Supplementary table 5 ). This clonal expansion during treatment and the identification of a kinaseimpaired BRAF mutation in a primary resistant tumor (C1011BL) substantiates a role of these mutations in cetuximab resistance. DNA copy number profiles generated from ctDNA at PD furthermore identified amplifications of MET and KRAS in 3 and 2 cases, respectively ( Fig.2c and Supplementary fig.9 ). The FGF10 amplification found in the C1027PD1-biopsy was also identified in ctDNA at PD. Overall, ctDNA-sequencing revealed genetic drivers of AR in 8/9pts and frequent polyclonal resistance, similar to published ctDNA results 13 . We next used TP53 mutations, detected in all ctDNA samples, to estimate the fraction of the cancer cell population represented in the ctDNA that harbored AR mutations at PD (Supplementary table 5 ). All detected resistance driver mutations taken together in each tumor were confined to a median of 21% of the cancer cells in the population (Fig.2d) . The fraction of cancer cells that harbor an amplification cannot be estimated from ctDNA data as the absolute number of DNA copies in such subclones are unknown. Thus, only considering the five cases without concurrent AR amplifications in ctDNA, we still found a resistance gap with no detectable resistance mechanism in 49-100% of cancer cells sampled by ctDNA (Fig.2d) . Although ctDNA and amplicon deep-sequencing may not identify very small subclones with genetic resistance drivers due to sensitivity limits, we hypothesized based on the ctDNA results and the inability to define genetic AR drivers in 9/14 biopsies (64%) from radiologically progressing metastases, that non-genetic resistance mechanisms may exist.
Transcriptomic characteristics and their association with acquired resistance
The CMS2-and TA-subtypes significantly associated with cetuximab sensitivity at BL. Based on the observation that mechanisms of acquired drug resistance are often similar to those conferring primary resistance, we investigated whether subtype-identity may have a role in AR.
We first analysed PD-biopsies from tumors with prolonged benefit in which no genetic aberrations of cetuximab resistance genes had been found. Strikingly, 5/7 cases (71%) showed a switch from the cetuximab sensitive CMS2 subtype to the CMS4 subtype and 4/7 (57%) showed a TA to Stem-Like (SL) subtype switch ( Fig.3a, Supplementary fig.5 ). In contrast, no CMS2/TA to CMS4/SL switches occurred in 6pts with primary PD. Switching from the cetuximab sensitive CMS2/TAsubtype to the CMS4/SL-subtype in the majority of PD-samples without identifiable genetic resistance mechanisms suggested that this contributes to acquired cetuximab resistance.
Transforming growth factor beta (TGFβ)-expression is a defining characteristic of the CMS4/SL-subtypes. TGFβ1 and TGFβ2 RNA expression indeed significantly increased (3.1-and 2.9-fold increase in the means, p<0.05, paired t-test) in tumors undergoing a CMS2>4 switch (Fig.3b ).
TGFβ3 mean expression increased 7.2-fold at PD but this did not reach significance. A high level of TGFβ-activity in these samples was confirmed by the upregulation of a TGFβ-activated transcriptomic signature and of an epithelial to mesenchymal transition (EMT) signature which can be induced by TGFβ (Fig.3c ).
CMS4 CRCs are enriched with cancer associated fibroblasts (CAFs) which are a major source of TGFβ and of mitogenic growth factors 38 . Applying the MCPCounter 39 algorithm to RNA-sequencing data to bioinformatically assess the fibroblast content in the microenvironment confirmed significant increase in their abundance in PD-biopsies that had switched to the CMS4-subtype (Fig.3d ). CMS2>4 subtype switches correspondingly increased the expression of growth factors that conferred cetuximab resistance in vitro (Fig.3b) , including FGF1 and FGF2 (2.3-and 3.1-fold increase in the means, respectively) which activate multiple FGFRs and of the MET-ligand HGF which increased 8.3-fold, although the latter was not significant (p=0.1). In contrast, mean expression of the main EGFR-activating ligands in CRC, AREG and EREG, decreased 2.4-fold and 2.3-fold after subtype switching but this was not significant.
Conditioned media from cancer-associated fibroblasts (CAFs) can confer cetuximab resistance in colorectal cancer stem-like cells 40 . We questioned whether CAFs also promote resistance in well described cetuximab-sensitive CRC cell lines. Treatment with conditioned medium from immortalized CRC CAFs indeed rescued growth and maintained ERK phosphorylation in DiFi and LIM1215 CRC cell lines despite cetuximab treatment ( Fig.3e and f).
Although this supports CMS2>CMS4 transitions and the associated increase in CAFs and mitogenic growth factors as a novel mechanism of acquired cetuximab resistance in CRC patients, two BL-biopsies from patients that subsequently achieved prolonged benefit from cetuximab therapy also displayed the CMS4-subtype. Thus, CMS4 identity does not invariably confer resistance.
RNA-Sequencing data from BL-and PD-biopsies was available from one of these cases (C1020) and showed that TGFβ2 (4.4-fold), TGFβ3 (4.2-fold), HGF (2.7-fold) and FGF2 (1.6-fold) all increased from BL to PD (Supplementary table 6 ). This suggests a model where a gradual increase in growth factorexpression in a process associated with fibroblast infiltration and the acquisition of CMS4-subtype promotes resistance. This can evolve concurrently with genetic resistance in distinct subclones within the same patient, as demonstrated for cases that acquired CMS4 in a PD-biopsy while ctDNA showed the evolution of genetic resistance drivers in subclones (C1027, C1041, C1044). This parallel evolution of molecularly and functionally diverse resistance mechanisms within the same patients hinders the development of signalling pathway-targeting strategies to prevent or reverse resistance.
The identification of new therapeutics that apply distinct selection pressures are hence a major need.
Cetuximab impacts the cancer immune landscape
The IgG1-antibody cetuximab triggered immunogenic cell death and increased CRC immunogenicity in murine models 41 . Yet, whether effective cetuximab treatment promotes cancer immune responses in patients is unknown. We investigated this to explore potential opportunities to target cetuximab resistant CRCs with immunotherapy.
We first applied the cytolytic activity (CYT) signature 42 , which estimates the abundance of cytotoxic immune cells from RNA-expression data (Fig.4a) . The mean CYT did not differ between BLbiopsies from tumors with prolonged benefit vs. those with primary progression (p=0.11, t-test).
However, the mean CYT increased 5.9-fold from BL to PD in CRCs with prolonged benefit but not in those with primary progression, demonstrating that effective cetuximab treatment increased cytotoxic immune infiltrates. CYT remained relatively low in two tumors with prolonged benefit that showed no radiological shrinkage (C1018, C1030), suggesting that cancer cell death induction is required to stimulate cytotoxic cell infiltration. The largest CYT increases occurred in cases switching to the CMS4-subtype which is associated with an inflamed phenotype 29 . However, the median CYT in PD-biopsies of the five cases that switched to the CMS4-subtype was still 3-fold higher than in the five BL-biopsies classed as CMS4 prior to cetuximab exposure (Fig.4a) . Hence, increased CYT after cetuximab therapy cannot be attributed to transcriptomic subtype changes alone.
Next, we bioinformatically inferred the abundance of 28 immune cell types from RNAexpression data 43 . A significant increase of T-cells that promote and execute adaptive immune responses, including all assessed CD8 T-cell subtypes, effector-memory CD4 and Th1 subtype T-cells, in PD-samples taken after cetuximab responses was observed (Fig.4b ). Some immune cell subtypes which can dampen effective cytotoxic immune responses, including regulatory T-cells and myeloidderived suppressor cells (MDSCs), also significantly increased. In contrast, immune cell infiltrates did not change in primary progressors. The presence of BATF3-positive dendritic cells (DCs) which crosspresent antigens from dying cancer cells to CD8 T-cells is critical for immunotherapy efficacy in melanoma 44 . Applying a BATF3-DC score 45 showed a significant increase at PD in tumors that had responded to cetuximab (1.7-fold increase, p=0.035) but no change in primary progressors (1.1-fold change, p=0.68, Fig.4c ). Thus, several critical immune cell lineages for effective recognition of tumors by the adaptive immune system are enriched in tumors that responded to cetuximab.
To ascertain changes in immune infiltrates, we stained for CD8+, CD4+, and regulatory T-cells (FOXP3+ and CD4+) in paired BL and PD FFPE-biopsies available from 5pts with prolonged benefit and from 5 primary progressors (Fig.4d) . CD8 T-cell densities increased significantly at PD compared to BL (2.0-fold change in means, p=0.047) in patients who responded to cetuximab. Mean of CD4+
and regulatory T-cells increased numerically but this was not significant (1.9-fold, p=0.057 and 2.2 fold, p=0.063), possibly because of the small number of cases available for this analysis. Thus, cetuximab treatment promotes T-cell infiltration of CRCs that respond and these are present at the time of progression. TGFβ has immunosuppressive effects, including the promotion of a T-cell excluded phenotype which can contribute to anti-PDL1 immunotherapy resistance 46 . Despite increased TGFβ expression after CMS2>CMS4 switching, CD8 T-cell infiltrates were present in intratumoral stroma in such PD-biopsies (Fig.4e) , perhaps suggesting that the dynamic changes during response and re-growth prevent exclusion of T-cells.
We furthermore applied a signature of T-cell associated inflammation which is predictive for immune checkpoint-inhibitor benefit in several cancer types 47 . This significantly increased from BL to PD in responders but not in primary progressors (Fig.4f) . Effective cetuximab therapy hence not only augments immune infiltrates including cytotoxic T-cells, but also T-cell associated inflammation which may indicate enhanced T-cell recognition of cancer cells. We finally questioned whether changes in immune infiltrates were accompanied by altered expression of immune-checkpoints or chemokine receptors which can be targeted by current immunotherapy agents. The immunecheckpoints LAG3, PDL1, TIM3 and GITR and the chemokine receptor CXCR2, which promotes myeloid cell infiltration, were significantly upregulated (Fig.4g) . The up-regulation of immune-checkpoints may restrain T-cell infiltrates and could provide opportunities to develop novel therapeutic strategies following cetuximab failure.
DISCUSSION
This prospective trial revealed novel associations of biallelic NF1 loss and of non-canonical RAS/RAF-aberrations with primary resistance to single agent cetuximab. While KRAS A18D and L19F, and BRAF mutations other than V600E were rare in large CRC cohorts (each <1%) 48, 49 , NF1 mutations have been reported in ~5% of cases and successful validation as a predictive marker in randomized trials could spare these patients ineffective treatment. Our results are supported by a study describing an association of NF1 mutations with poor PFS with cetuximab in combination with chemotherapy 50 , although 3 out of 4 were missense mutations with unknown effects on NF1 function and there was no testing for loss of heterozygosity.
In contrast to previous reports 7, 51 , neither PIK3CA mutations nor FGFR1 aberrations clearly associated with primary resistance. Particularly PIK3CA exon 20 mutations have been described to confer resistance to anti-EGFR-Ab in combination with chemotherapy, however we found the exon 20 mutation H1047R in a responder but also in combination with a PIK3CA amplification in a primary progressor. Concomitant copy number aberrations or the use of single agent cetuximab may explain these differences. The small sample size furthermore warrants cautious interpretation of these results.
We found a strikingly lower frequency of acquired resistance driver mutations in RAS and EGFR in PD-biopsies than anticipated based on the pervasive detection of these drivers in cetuximab treated patients analyzed by ctDNA 52 . The absence of genetic aberrations of cetuximab resistance driver genes in 64% of PD-biopsies, corroborated by ctDNA analysis which did not detect resistance drivers in 45-100% of the cancer cell population sampled, highlights a significant unexplained resistance gap. The majority of PD biopsies without identifiable genetic resistance drivers no longer displayed the cetuximab-sensitive CMS2/TA-subtype found before treatment initiation but the CMS4/SL-subtype which is rich in fibroblast and in growth factors that confer cetuximab resistance in vitro. Together with the inability to identify genetic resistance drivers in these biopsies from radiologically progressing metastases strongly suggests that subtype switching and associated stromal remodelling is a novel mechanism of acquired resistance to single agent cetuximab. This could explain similar genetic results in a series of 37 PD biopsies which found no aberrations in RAS, BRAF or EGFR in 46% of biopsies with acquired anti-EGFR-Ab resistance 53 .
These data demonstrate the limitations of ctDNA analysis which is restricted to the identification of genetic resistance mechanisms and the importance of parallel tissue analyses with multi-omics approaches. They furthermore portray a cetuximab resistance landscape resembling that of EGFR-inhibitors in lung cancer or BRAF-inhibitors in melanoma where non-genetic resistance can occur. Lung cancers that acquired resistance but showed no genetic resistance drivers can upregulate growth factors which activate bypass signalling pathways or EMT [54] [55] [56] as alternative resistance mechanisms and fibroblast-mediated stromal remodelling can confer acquired BRAFinhibitor resistance in melanomas 57 .
Combinatorial drug treatment approaches to reverse acquired cetuximab resistance in CRC appear challenging, due to toxicities that will most likely arise when attempting to combine multiple signalling-pathway inhibitors and because of the inability to effectively target RAS-mutant clones which evolved in 4/9pts. However, strategies to delay resistance by preventing subtype switching, for example by targeting TGFβ, a master-regulator of the CMS4/SL-subtype, could be assessed.
Our analysis of the immune landscape in CRCs that responded to cetuximab and then The identification of novel biomarkers of primary and acquired resistance to cetuximab therapy in DNA and RNA from CRC tumor biopsies was the primary endpoint of the study. The study recruited to the recruitment target of 30 patients that had been treated and had BL and PD samples available for genetic analyses. After removing cases with insufficient DNA yield or tumor content based on sequencing results, data from 24 paired BL and PD samples was available for mutation and copy number analysis. 11 cases from which only a BL biopsy was available were included in the analysis. Secondary endpoints included the identification and validation of novel biomarkers for resistance and response to cetuximab in RNA and ctDNA. The trial protocol also permitted further exploratory molecular analyses.
The efficacy parameters including partial response and stable disease were measured using RECIST v1.1 criteria. Progression free survival (PFS) was measured from start of treatment to date of progression or death from any cause. Overall survival (OS) was defined as time from start of treatment to death of any cause. Patients without an event were censored at last follow up before PFS and OS were estimated.
The cohort was dichotomized into primary progressors who had PD before or on the first per protocol CT scan, scheduled at 12 weeks from the start of cetuximab treatment. This was performed at a median of 12 weeks with a range of 9-16 weeks on treatment. Patients with prolonged benefit were defined as those who remained progression free at the time of this scan.
Samples from healthy donors were collected for ctDNA sequencing after obtaining written informed consent through the 'Improving Outcomes in Cancer' biobanking protocol at the Barts Cancer Centre (PI: Powles), which was approved by the UK national ethics committee (Research Ethics Committee approval: 13/EM/0327).
Sample preparation
DNA and RNA were extracted simultaneously from snap frozen biopsies using the Qiagen All
Prep DNA/RNA Micro Kit following the manufacturer's instructions. Matched normal DNA was extracted from blood samples using the Qiagen DNA Blood Mini Kit. DNA concentration was measured using the Qubit dsDNA Broad Range Assay Kit, and integrity checked by agarose gel electrophoresis. A minimum quantity of 500 ng, and where available 2 µg of DNA, was used for next generation sequencing. RNA from biopsies which were successfully DNA sequenced was subjected to RNA-Sequencing if a sufficient quantity (>125ng) and quality (RIN>5.5) was confirmed by electrophoresis on the Agilent 2100 Bioanalyzer. Blood for circulating tumor DNA analysis was collected in EDTA tubes and centrifuged within 2 hours (10min, 1600g) to separate plasma, which was stored at -80°C. Upon thawing, samples were further centrifuged (10min, 16000g, 4°C). ctDNA was extracted from up to 4 ml plasma per patient and from 2x4 ml from healthy donors using the Qiagen QIAamp Circulating Nucleic Acid Kit. ctDNA was quantified on the Agilent 2100 Bioanalyzer. 
Whole exome/genome DNA sequencing
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Somatic mutation analysis
Tumor and germline DNA sequencing results were assessed for matching SNP profiles to check for potential sample swaps. This identified one case where germline DNA and tumor DNA SNP profiles differed and this was removed from the analysis. For single nucleotide variant (SNV) calls we SnpSift to filter heterozygous loci with minimum depth 50. We further extracted positions spaced 500bp apart in the whole genome samples. VarScan2 was used to call the tumor sample BAMs at these locations to generate B-Allele Frequency (BAF) data as input for CNVKit.
DNA copy number aberration analysis
We generated basic access and antitarget files to indicate the accessible sequence regions.
This excluded blacklisted regions suggested by CNVKit and the HLA region. We then generated a pooled normal sample and used the winsorize and pcf functions within copynumber 68 to identify further outlier positions and regions of highly uneven coverage. These regions were merged to ensure consistency across all data.
CNVKit was run with matched normals along with the adjusted access and antitarget files.
For the segmentation step we ran pcf from the R-package copynumber. Breakpoints from this segmentation step were then fed into Sequenza 69 (v2.1.2) to calculate estimates of purity/ploidy and these values were used as a guide to recenter and scale the LogR profiles in CNVKit. BAF and LogR profiles were also manually reviewed by two researchers to determine their likely integer copy number states. Adjustments were made in cases where both manual reviews identified a consensus solution that differed from the bioinformatically generated integer copy number profile.
Furthermore, BL/PD sample pairs where the ploidy of one sample was close to double the ploidy of the other sample and copy number profiles were highly similar (suggestive of a genome doubling event), the sample with lower ploidy was adjusted to a the likely genome-doubled higher state to facilitate a direct comparison of copy number changes, unless clear evidence of BAF and LogR profiles suggested otherwise. These adjustments were made in samples C1004PD, C1022PD, C1025PD, C1027PD1, C1030PD, C1043BL where both manual reviews supported a different solution to Sequenza.
Analysis of gene amplifications
Amplifications were defined as a 3-fold or greater increase on the ploidy of a sample, a substantial loss event as a 3-fold or greater decrease on the ploidy state and a homozygous deletion as CN=0. Amplification and loss threshold values were rounded to the nearest integer copy number state. Ploidy was estimated as follows, Ploidy = (CN Absolute x SegmentLength) / Σ(SegmentLength)
with CN Absolute representing the unrounded copy number estimate and SegmentLength the genomic length between segment break points. BL and PD biopsy pairs were compared to identify which cases had acquired amplifications at PD that were absent at BL. table 3) . In order to maximize the sensitivity for the detection of resistance mutations, these were called if at least 2 independent variant reads were identified at a mutational hotspot position and encoded for a recurrently observed amino acid change in the specific gene. Genome-wide copy number profiles were constructed using CNVKit run in batch mode with Antitarget average size 30 kb as described 36 .
Deep amplicon sequencing
ctDNA sequenced from healthy donors 36 was used as the normal reference dataset. Copy number profiles generated from ctDNA were aligned with copy number profiles showing absolute copy numbers from matched biopsies and the closest integer copy number was assigned to TP53 and mutated cetuximab resistance driver genes for the subclonality analysis.
RNA-sequencing
NEB polyA kit was used to select the mRNA. Strand specific libraries were generated from the mRNA using the NEB ultra directional kit. Illumina paired-end libraries were sequenced on an Illumina HiSeq2500 using v4 chemistry acquiring 2 x 100 bp reads. Bcl2fastq software (v1.8.4, Illumina) was used for converting the raw basecalls to fastqs and to further demultiplex the sequencing data.
Tophat2 spliced alignment software 70 (v2.0.7) was used to align reads to the GRCh37 (hg19) release-87 human reference genome in combination with Bowtie2 71 (v2.1.0). FeatureCounts 72 was used to perform read summarization. Sample QC was performed using Picard Tools
CollectRnaSeqMetrics. We excluded 2 samples (C1006BL and C1007BL) with fewer than 10% of reads aligning to exonic regions. Lowly expressed genes were filtered using a cpm threshold equivalent to 10/L, where L is the minimum library size in millions 73 . Sample batch effects were assessed using principal component analysis and did not require corrective action. Counts were normalized for library size using estimateSizeFactors in Deseq2 74 . FPKM data were generated using the fpkm function in Deseq2. For downstream analysis all data were filtered for protein coding genes using the GTF annotation file and filtering on the gene_biotype column.
Statistical analyses
All statistical analysis was performed using R (v3. Kaplan-Meier method was used to estimate OS and PFS probability. The Mann-Whitney statistical test was applied to compare ssGSEA rank scores of 28 immune cell populations followed by False Discovery Rate correction and a q value ≤ 0.1 was considered statistically significant.
Cancer cell content analysis
The cancer cell content of each sequenced sample was assessed based on the variant allele frequency (VAF) of somatic mutations and samples with an estimated cancer cell content below 10%
were removed from the analysis as the sequencing depth was insufficient to accurately detect mutations in these samples 61 . As the majority of mutations are heterozygous and hence present in half of the DNA copies of the cancer cells, 2xVAF can be used to approximation the fraction of cancer cells in a sample. This led to the exclusion of four samples (C1001BL, C1009BL, C1010BL, C1042BL) as shown in the Consort diagram (Supplementary fig.1a ). The median estimated cancer cell content across the remaining 60 samples was 41% (Supplementary table 1) .
Subclonality analysis exome sequencing data
The clonal status of mutations was assessed using the allele specific copy number generated in the CNVKit solution. We estimated the cancer cell fraction (CCF) using the phyloCCF method as described by Jamal-Hanjani et al. 75 . We then inferred the mutation copy number (i.e. the number of alleles harbouring the mutation) and assigned clonal/subclonal status to each variant using the criteria described by McGranahan et al. 76 .
Subclonality analysis in ctDNA and amplicon sequencing data
Variant allele frequencies of TP53 mutations, of hotspot resistance driver mutations in KRAS, NRAS, BRAF and EGFR and of the EGFR mutation D278N were extracted from ctDNA BAM files. TP53 mutation VAFs were used to calculate what fraction of the ctDNA was of cancer cell origin by correcting for the influence of copy number aberrations using the following formula:
CCF =2*VAF/(Copies mutated + 2*VAF -VAF*Copies total )
with CCF indicating the cancer cell fraction, Copies mutated the number of copies that harbored the TP53 mutation and Copies total the absolute copy number of the TP53 locus. Clonality analysis of TP53 mutation showed clonal mutations and loss of heterozygosity of the TP53 locus for all tumour biopsies with the exception of C1027 which harbored two TP53 mutations, one present on four copies of chromosome 17p and one on two copies, suggesting biallelic inactivation through two distinct mutation events. TP53 Copies mutated and Copies total were equal for tumors with TP53 LOH and in 1027 the VAFs of both TP53 mutations were taken together and the sum of all chromosome 17p copies were used to estimate CCF.
The same formula was then resolved to calculate the expected VAF of a clonal mutation given the CCF of the ctDNA sample and the local copy number state of this mutation: VAF =(CCF*Copies mutated )/(CCF*Copies total +2-2*CCF)
Copies total for all mutations were inferred from ctDNA copy number profiles that had been close matched to the integer copy number states of biopsies (Supplementary fig 9) . For subclonality calculation, we furthermore assumed that resistance drivers were only mutated on a single gene copy (i.e. Copies mutated =1, which is likely as they are thought to have a dominant effect). This assumption furthermore maximized the estimated fraction of cancer cells that harbor a resistance driver mutation, hence providing a conservative measure of the resistance gap. The fraction of the total CCF in ctDNA that harbors an observed resistance driver mutation was then calculated by dividing the observed VAF by the expected VAF for a mutation that is 100% clonal. We then estimated the maximum fraction of all cancer cells that harbored resistance driver mutations in a sample as the sum of the CCF values of all individual resistance driver mutations in that sample.
Colorectal cancer subtyping
Consensus Molecular Subtypes 29 were assigned using CMScaller 77 . The CMScaller function was run with raw count data and setting 'RNASeq=TRUE'. Each sample was assigned the subtype with the shortest distance according to the inbuilt nearest template prediction (NTP) 78 . The
CMScaller classification was considered low confidence if FDR >0.01. Samples were also assigned to the molecular CRC subtypes, as described by Sadanandam et al. 10 . To minimize technical differences in subtype assignment we generated data normalized using the same approach as CMScaller 
Immune cell infiltrate analysis
The cytolytic activity (CYT) was calculated as the geometric mean of the GZMA and PRF1
genes (normalized expression values as input, offset by 1.0). The BATF3-DC signature was calculated as the mean of the normalized expression values of the genes in this signature. FPKM normalized RNA sequencing data and published immune cell metagenes 43 were used as input into the single sample gene set enrichment analysis (ssGSEA) algorithm using default settings to determine immune cell enrichments in each sample as described 79 .
The Microenvironment Cell Populations (MCP)-counter algorithm 39 was used as an independent bioinformatics tool to assess immune cell enrichment. Data were normalized using limma 80 voom and the MCPCounter function run with HUGO_symbols chosen as featuresType.
Immunohistochemistry
5 µm slides were cut from FFPE blocks and triple stained as described 81 . 5 representative tumor areas of 0.05 mm 2 were identified per slide and CD8+ cells, FOXP3+ and CD4+ cells and CD4+
FOXP3-were quantified in each of the selected areas at x40 magnification using ImageJ software.
Densities were calculated as cells/mm 2 . Immune cell scoring was performed blinded.
Cell lines
DiFi and LIM1215 cell lines were a gift from the Valeri Lab at ICR. NIH-3T3 cells were a gift from the Huang Lab at ICR. DiFi cells were cultured in RPMI-1640 (Gibco), GlutaMax (Gibco), 5% FBS.
LIM1215 cells were cultured in RPMI-1640, 10% FBS, hydrocortisone (Gibco), 1-thioglycerol (Sigma) and insulin (Gibco). NIH-3T3 cells were cultured in DMEM (Gibco), GlutaMax (Gibco) and 10% FBS.
Human fibroblasts from rectal carcinomas which have been immortalized using hTERT virus (pCSII vector backbone) (RC11) were a gift from Fernando Calvo, initially provided by Danijela Vignjevic (Institute Curie, France) 82 . Fibroblasts were cultured in DMEM (Sigma), GlutaMax (Gibco), 10% FBS, 1% insulin-selenium-transferrin (ITS, Gibco). Conditioned media was harvested from flasks of confluent RC11 cells after 72h.
Drug Assays
FGF10 rescue experiments were performed in DiFi and LIM1215 colorectal cancer cell lines treated with cetuximab and FGF10 (Peprotech) for 7 days. Treatments were replenished with fresh media after 3 days. EGFR mutant experiments were performed in LIM1215 cells. Cells were treated with cetuximab for 5 days. DiFi and LIM1215 cells were seeded in standard media or CAFconditioned media and treated with cetuximab for 5 days. All experiments were perfumed in six replicates. Viability was assessed using CellTiter Blue reagent (Promega) for all assays.
DNA constructs
The Gateway Entry clone R777-E053-Hs.EGFR was a gift from Dominic Esposito (Addgene plasmid #70337). Site directed mutagenesis using QuikChange Lightning (Agilent) and custom designed primers (5'-CCTCGGGGTTCACATTCATCTGGTACGTGGT/5'-ACCACGTACCAGATGAATGTGAACCCCGAGG) was used to generate the EGFR-D278N mutant. The fulllength sequence was assessed using Sanger sequencing to confirm presence of the intended mutation and that no other mutations had been inserted before Gateway recombination into the lentiviral expression construct pLX304 (a gift from David Root, Addgene plasmid #25890). HEK293T cells were infected with the lentiviral constructs pLX304-WT and pLX304-D278N in combination with packaging plasmids psPAX and pMD2.G (a gift from Didier Trono, Addgene #12260 and #12259 respectively). LIM1215 and NIH-3T3 cells were transduced with the resultant viral supernatants in the presence of Polybrene (8 µg/mL), and selected with 0.5 µg/mL Blasticidin.
Western Blotting
Total cell lysates were prepared using NP-40 buffer supplemented with protease and phosphatase inhibitors (Sigma). Samples were resolved by electrophoresis on SDS-PAGE gels for
Western blotting. Primary antibodies used were p-ERK (Cell Signalling Technologies #9101), ERK (Cell Signalling Technologies #9102), p-EGFR (Cell Signalling Technologies #2236) and EGFR (Cell Signalling Technologies #2232). Bands were detected using HRP-labelled secondary antibodies and ECL Prime, GE Healthcare ), followed by visualisation on an Azure Biosystems C300 detection system.
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